Make in-body spaceship available to everyone.
To develop nanotechnology that treats cancer patients effectively but with smallest toxicities.
Pioneering the Interleukin-12 prodrug Axis
Broad applicability of Red Arrow prodrug technology including:
Small peptide to antibody full chain
Cationic protein to anionic protein
Lead asset – RA001 – IND planned for 2025
Based on novel technologies developed by a pioneer of nanomedicine, Prof. Dr. Horacio Cabral from the University of Tokyo
Main Investors: The University of Tokyo Edge Capital (UTEC)